Loading stock data…
CRIS
$0.59-0.01 (-1.33%)
Market ClosedLast close May 1
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Curis, Inc. in the Healthcare sector is trading at $0.59. The stock is currently near its 52-week low of $0.49, remaining 51.9% below its 200-day moving average. Technical signals show neutral RSI of 45 and bullish MACD crossover, explaining why CRIS maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 45) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$0.59
Potential Upside
5%
Whystock Fair Value$0.62
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus3 analysts
Mean target$14.00+2264.9%
Range$5.00 – $20.00
Fundamentals
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inh...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$24.56M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.14
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1079.51%
Volume
Today's trading volume
156,002
Recent News
Kiniksa Pharmaceuticals International, plc (KNSA) Tops Q1 Earnings and Revenue Estimates
Kiniksa Pharmaceuticals International, plc (KNSA) delivered earnings and revenue surprises of +50.00% and +5.24%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Curis (CRIS) Upgraded to Buy: What Does It Mean for the Stock?
Curis (CRIS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Curis Inc (CRIS) Q4 2025 Earnings Call Highlights: A Turnaround with Strong Quarterly Profit ...
Curis Inc (CRIS) reports a significant quarterly profit, strategic advancements in clinical trials, and a solid financial outlook despite annual losses.
Curis, Inc. Q4 2025 Earnings Call Summary
Moby summary of Curis, Inc.'s Q4 2025 earnings call
Curis (CRIS) Q4 2025 Earnings Call Transcript
As you recall, last quarter we engaged with a number of KOLs who were excited and highly supportive about expanding our emavusertib studies into additional NHL subtypes. Over the last decade, BTK inhibitors have become the standard of care in CLL and NHL because of their ability to help patients achieve objective responses.